Our previous retrospective longitudinal clinical studies developed a seven-gene qRT-PCR microfluidic assay for NSCLC prognostic and prediction of chemotherapeutic benefits [10], including ABCC4, CCL19, SLC39A8, CD27, FUT7, DAG1, and ZNF71. This evidence concerns the gene ZNF71 and non-small cell lung carcinoma.